On the one hand, studies have found that the anti-tumor effect of GBP1 is reflected in colorectal cancer, liver cancer, epithelial ovarian cancer, high-grade serous ovarian cancer and other cancers, and high expression of GBP1 is associated with better survival prognosis in these cancer patients [12–15]. This evidence concerns the gene GBP1 and ovarian serous adenocarcinoma.